Cargando…
Predictive value of EGFR mutation in non–small‐cell lung cancer patients treated with platinum doublet postoperative chemotherapy
The mutation status of tumor tissue DNA (n = 389) of resected stage II‐III non‐squamous non–small‐cell lung cancer (Ns‐NSCLC) was analyzed using targeted deep sequencing as an exploratory biomarker study (JIPANG‐TR) for the JIPANG study, a randomized phase III study of pemetrexed/cisplatin (Pem/Cis)...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8748214/ https://www.ncbi.nlm.nih.gov/pubmed/34689382 http://dx.doi.org/10.1111/cas.15171 |
_version_ | 1784630978089582592 |
---|---|
author | Takahashi, Toshiaki Sakai, Kazuko Kenmotsu, Hirotsugu Yoh, Kiyotaka Daga, Haruko Ohira, Tatsuo Ueno, Tsuyoshi Aoki, Tadashi Hayashi, Hidetoshi Yamazaki, Koji Hosomi, Yukio Chen‐Yoshikawa, Toyofumi F. Okumura, Norihito Takiguchi, Yuichi Sekine, Akimasa Haruki, Tomohiro Yamamoto, Hiromasa Sato, Yuki Akamatsu, Hiroaki Seto, Takashi Saeki, Sho Sugio, Kenji Nishio, Makoto Inokawa, Hidetoshi Yamamoto, Nobuyuki Nishio, Kazuto Tsuboi, Masahiro |
author_facet | Takahashi, Toshiaki Sakai, Kazuko Kenmotsu, Hirotsugu Yoh, Kiyotaka Daga, Haruko Ohira, Tatsuo Ueno, Tsuyoshi Aoki, Tadashi Hayashi, Hidetoshi Yamazaki, Koji Hosomi, Yukio Chen‐Yoshikawa, Toyofumi F. Okumura, Norihito Takiguchi, Yuichi Sekine, Akimasa Haruki, Tomohiro Yamamoto, Hiromasa Sato, Yuki Akamatsu, Hiroaki Seto, Takashi Saeki, Sho Sugio, Kenji Nishio, Makoto Inokawa, Hidetoshi Yamamoto, Nobuyuki Nishio, Kazuto Tsuboi, Masahiro |
author_sort | Takahashi, Toshiaki |
collection | PubMed |
description | The mutation status of tumor tissue DNA (n = 389) of resected stage II‐III non‐squamous non–small‐cell lung cancer (Ns‐NSCLC) was analyzed using targeted deep sequencing as an exploratory biomarker study (JIPANG‐TR) for the JIPANG study, a randomized phase III study of pemetrexed/cisplatin (Pem/Cis) vs vinorelbine/cisplatin (Vnr/Cis). The TP53 mutation, common EGFR mutations (exon 19 deletion and L858R), and KRAS mutations were frequently detected. The frequency of the EGFR mutation was significant among female patients. Patients with an EGFR mutation‐positive status had a significantly shorter recurrence‐free survival (RFS) time (24 mo vs not reached) (HR, 1.64; 95% CI, 1.22‐2.21; P = .0011 for EGFR mutation status). Multivariable analysis identified both the pathological stage and EGFR mutation status as independent prognostic factors for RFS (HR, 1.78; 95% CI, 1.30‐2.44; P = .0003 for disease stage; and HR, 1.57; 95% CI, 1.15‐2.16; P = .0050 for EGFR mutation status). This study demonstrated that the EGFR mutation has either a poor prognostic or predictive impact on a poor response to postoperative chemotherapy with platinum doublet chemotherapy for stage II‐III Ns‐NSCLC patients. This result supports a role for mandatory molecular diagnosis of early‐stage Ns‐NSCLC for precision oncology and signifies the importance of adjuvant for the 3rd generation tyrosine kinase inhibitor rather than platinum‐based chemotherapy. This study is registered with the UMIN Clinical Trial Registry (UMIN 000012237). |
format | Online Article Text |
id | pubmed-8748214 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-87482142022-01-14 Predictive value of EGFR mutation in non–small‐cell lung cancer patients treated with platinum doublet postoperative chemotherapy Takahashi, Toshiaki Sakai, Kazuko Kenmotsu, Hirotsugu Yoh, Kiyotaka Daga, Haruko Ohira, Tatsuo Ueno, Tsuyoshi Aoki, Tadashi Hayashi, Hidetoshi Yamazaki, Koji Hosomi, Yukio Chen‐Yoshikawa, Toyofumi F. Okumura, Norihito Takiguchi, Yuichi Sekine, Akimasa Haruki, Tomohiro Yamamoto, Hiromasa Sato, Yuki Akamatsu, Hiroaki Seto, Takashi Saeki, Sho Sugio, Kenji Nishio, Makoto Inokawa, Hidetoshi Yamamoto, Nobuyuki Nishio, Kazuto Tsuboi, Masahiro Cancer Sci Original Articles The mutation status of tumor tissue DNA (n = 389) of resected stage II‐III non‐squamous non–small‐cell lung cancer (Ns‐NSCLC) was analyzed using targeted deep sequencing as an exploratory biomarker study (JIPANG‐TR) for the JIPANG study, a randomized phase III study of pemetrexed/cisplatin (Pem/Cis) vs vinorelbine/cisplatin (Vnr/Cis). The TP53 mutation, common EGFR mutations (exon 19 deletion and L858R), and KRAS mutations were frequently detected. The frequency of the EGFR mutation was significant among female patients. Patients with an EGFR mutation‐positive status had a significantly shorter recurrence‐free survival (RFS) time (24 mo vs not reached) (HR, 1.64; 95% CI, 1.22‐2.21; P = .0011 for EGFR mutation status). Multivariable analysis identified both the pathological stage and EGFR mutation status as independent prognostic factors for RFS (HR, 1.78; 95% CI, 1.30‐2.44; P = .0003 for disease stage; and HR, 1.57; 95% CI, 1.15‐2.16; P = .0050 for EGFR mutation status). This study demonstrated that the EGFR mutation has either a poor prognostic or predictive impact on a poor response to postoperative chemotherapy with platinum doublet chemotherapy for stage II‐III Ns‐NSCLC patients. This result supports a role for mandatory molecular diagnosis of early‐stage Ns‐NSCLC for precision oncology and signifies the importance of adjuvant for the 3rd generation tyrosine kinase inhibitor rather than platinum‐based chemotherapy. This study is registered with the UMIN Clinical Trial Registry (UMIN 000012237). John Wiley and Sons Inc. 2021-11-07 2022-01 /pmc/articles/PMC8748214/ /pubmed/34689382 http://dx.doi.org/10.1111/cas.15171 Text en © 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes. |
spellingShingle | Original Articles Takahashi, Toshiaki Sakai, Kazuko Kenmotsu, Hirotsugu Yoh, Kiyotaka Daga, Haruko Ohira, Tatsuo Ueno, Tsuyoshi Aoki, Tadashi Hayashi, Hidetoshi Yamazaki, Koji Hosomi, Yukio Chen‐Yoshikawa, Toyofumi F. Okumura, Norihito Takiguchi, Yuichi Sekine, Akimasa Haruki, Tomohiro Yamamoto, Hiromasa Sato, Yuki Akamatsu, Hiroaki Seto, Takashi Saeki, Sho Sugio, Kenji Nishio, Makoto Inokawa, Hidetoshi Yamamoto, Nobuyuki Nishio, Kazuto Tsuboi, Masahiro Predictive value of EGFR mutation in non–small‐cell lung cancer patients treated with platinum doublet postoperative chemotherapy |
title | Predictive value of EGFR mutation in non–small‐cell lung cancer patients treated with platinum doublet postoperative chemotherapy |
title_full | Predictive value of EGFR mutation in non–small‐cell lung cancer patients treated with platinum doublet postoperative chemotherapy |
title_fullStr | Predictive value of EGFR mutation in non–small‐cell lung cancer patients treated with platinum doublet postoperative chemotherapy |
title_full_unstemmed | Predictive value of EGFR mutation in non–small‐cell lung cancer patients treated with platinum doublet postoperative chemotherapy |
title_short | Predictive value of EGFR mutation in non–small‐cell lung cancer patients treated with platinum doublet postoperative chemotherapy |
title_sort | predictive value of egfr mutation in non–small‐cell lung cancer patients treated with platinum doublet postoperative chemotherapy |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8748214/ https://www.ncbi.nlm.nih.gov/pubmed/34689382 http://dx.doi.org/10.1111/cas.15171 |
work_keys_str_mv | AT takahashitoshiaki predictivevalueofegfrmutationinnonsmallcelllungcancerpatientstreatedwithplatinumdoubletpostoperativechemotherapy AT sakaikazuko predictivevalueofegfrmutationinnonsmallcelllungcancerpatientstreatedwithplatinumdoubletpostoperativechemotherapy AT kenmotsuhirotsugu predictivevalueofegfrmutationinnonsmallcelllungcancerpatientstreatedwithplatinumdoubletpostoperativechemotherapy AT yohkiyotaka predictivevalueofegfrmutationinnonsmallcelllungcancerpatientstreatedwithplatinumdoubletpostoperativechemotherapy AT dagaharuko predictivevalueofegfrmutationinnonsmallcelllungcancerpatientstreatedwithplatinumdoubletpostoperativechemotherapy AT ohiratatsuo predictivevalueofegfrmutationinnonsmallcelllungcancerpatientstreatedwithplatinumdoubletpostoperativechemotherapy AT uenotsuyoshi predictivevalueofegfrmutationinnonsmallcelllungcancerpatientstreatedwithplatinumdoubletpostoperativechemotherapy AT aokitadashi predictivevalueofegfrmutationinnonsmallcelllungcancerpatientstreatedwithplatinumdoubletpostoperativechemotherapy AT hayashihidetoshi predictivevalueofegfrmutationinnonsmallcelllungcancerpatientstreatedwithplatinumdoubletpostoperativechemotherapy AT yamazakikoji predictivevalueofegfrmutationinnonsmallcelllungcancerpatientstreatedwithplatinumdoubletpostoperativechemotherapy AT hosomiyukio predictivevalueofegfrmutationinnonsmallcelllungcancerpatientstreatedwithplatinumdoubletpostoperativechemotherapy AT chenyoshikawatoyofumif predictivevalueofegfrmutationinnonsmallcelllungcancerpatientstreatedwithplatinumdoubletpostoperativechemotherapy AT okumuranorihito predictivevalueofegfrmutationinnonsmallcelllungcancerpatientstreatedwithplatinumdoubletpostoperativechemotherapy AT takiguchiyuichi predictivevalueofegfrmutationinnonsmallcelllungcancerpatientstreatedwithplatinumdoubletpostoperativechemotherapy AT sekineakimasa predictivevalueofegfrmutationinnonsmallcelllungcancerpatientstreatedwithplatinumdoubletpostoperativechemotherapy AT harukitomohiro predictivevalueofegfrmutationinnonsmallcelllungcancerpatientstreatedwithplatinumdoubletpostoperativechemotherapy AT yamamotohiromasa predictivevalueofegfrmutationinnonsmallcelllungcancerpatientstreatedwithplatinumdoubletpostoperativechemotherapy AT satoyuki predictivevalueofegfrmutationinnonsmallcelllungcancerpatientstreatedwithplatinumdoubletpostoperativechemotherapy AT akamatsuhiroaki predictivevalueofegfrmutationinnonsmallcelllungcancerpatientstreatedwithplatinumdoubletpostoperativechemotherapy AT setotakashi predictivevalueofegfrmutationinnonsmallcelllungcancerpatientstreatedwithplatinumdoubletpostoperativechemotherapy AT saekisho predictivevalueofegfrmutationinnonsmallcelllungcancerpatientstreatedwithplatinumdoubletpostoperativechemotherapy AT sugiokenji predictivevalueofegfrmutationinnonsmallcelllungcancerpatientstreatedwithplatinumdoubletpostoperativechemotherapy AT nishiomakoto predictivevalueofegfrmutationinnonsmallcelllungcancerpatientstreatedwithplatinumdoubletpostoperativechemotherapy AT inokawahidetoshi predictivevalueofegfrmutationinnonsmallcelllungcancerpatientstreatedwithplatinumdoubletpostoperativechemotherapy AT yamamotonobuyuki predictivevalueofegfrmutationinnonsmallcelllungcancerpatientstreatedwithplatinumdoubletpostoperativechemotherapy AT nishiokazuto predictivevalueofegfrmutationinnonsmallcelllungcancerpatientstreatedwithplatinumdoubletpostoperativechemotherapy AT tsuboimasahiro predictivevalueofegfrmutationinnonsmallcelllungcancerpatientstreatedwithplatinumdoubletpostoperativechemotherapy |